European Biotech Acquisition priced its IPO of 12 million units at $10 each — an upsize of 2 million more units than expected. Units begin trading today on the Nasdaq under EBACU. Each consists of one Class A ordinary share and one-third of one redeemable warrant. A whole warrant is exercisable at $11.50 for a share. Once the securities comprising the units begin separate trading, shares and warrants are expected to list under EBAC and EBACW, respectively.
The SPAC intends to target opportunities in the life sciences industry in Europe. Read more.
